Skip to content

Bill Nye the Science Guy is speaking at the 2024 Annual Ataxia Conference! Register now.  LEARN MORE!


A collection of resources for individuals and families affected by Spinocerebellar Ataxia Type 6 (SCA6).

SCA6 is caused by a genetic mutation that is passed on from parents to their children. For complete information about symptoms, diagnosis, and treatment of Ataxia, visit our What is Ataxia? page. This page contains NAF’s resources that are specific to SCA6.

Sign up for our mailing list to stay up-to-date on Ataxia news.


Clinical Care for SCA6

Presented by Anoopum Gupta, MD, PhD

SCA6 or Spinocerebellar Ataxia 6 is a rare neuromuscular disease. This webinar gave an overview of the causes and symptoms of the disease, the typical diagnostic journey for those affected, and what to expect for clinical care.

Research and Treatment Development for SCA6

Presented by Alanna Watt, PhD

This webinar taught us how SCA6 is studied and gave an overview of the current state of research and drug development for the disease.

NAF offers webinars on many topics to help you live better with Ataxia. Visit to find other helpful presentations.

Research Pipeline

This is a visual tool created to show the progress of all SCA6 therapies that are currently being developed. Along the vertical axis, treatments are grouped by their mechanism, or how the drug works. The horizontal axis shows the stage of research where the drug is in development. Phases 1 through 3 involve clinical trials with human participants. Visit the SCA6 Pipeline page for more details.

Graph depicting the phase of drug development for various drugs to treat SCA6

Please note that a drug’s status is subject to change. Please visit for the most current information available for specific therapies. Detailed information is available for some of the drugs listed.

Participate in Research and Treatment Development

Participating in a research study or clinical trial is one way to take an active role in furthering understanding and treatment of Ataxia. It is also a way to get access to new treatment options before they are widely available. To find studies that are enrolling patients, visit our Help Develop New Treatments page.

SCA6 Information

Spinocerebellar Ataxia type 6 (SCA6) is one type of Ataxia among a group of inherited diseases of the central nervous system. It is one of the CAG repeat/polyglutamine disorders. SCA6 is caused by a defect in a gene that makes a protein called a transcription factor, that regulates expression of other genes in the cerebellum. The genetic defect in this protein results in degenerations of primarily Purkinje cells of the cerebellum.

The frequency of SCA6 varies considerably according to geographical area. For instance, SCA6 represents only about 2 percent of the cases of dominant spinocerebellar Ataxia in Italy, but it has been shown to represent as high as 31 percent in Japan. In the United States, SCA6 represents about 15 percent of all cases of dominant hereditary Ataxia.

SCA6 Symptoms

Like many other forms of Ataxia, SCA6 is marked by incoordination. In fact, the word Ataxia means incoordination. In most cases, the first symptoms of SCA6 are unsteady gait, stumbling, and imbalance. In about 10 percent of the cases, the first symptom is unclear speech (dysarthria). As the disease progresses, incoordination of both upper and lower limbs, tremors, and slurred speech will eventually be present in everyone with SCA6. Double vision or other visual disturbances occur in about 50 percent of the people with SCA6. In later stages, difficulty swallowing (dysphagia) is common.

SCA6 Prognosis

Age at onset of SCA6 symptoms ranges from 19 to 71 years old. The severity of symptoms also varies considerably, even within families. Most often, it is a late onset disorder with symptoms first occurring between 43 and 52 years of age. It usually progresses slowly. Lifespan generally is not shortened by the disease.

SCA6 Genetics

SCA6 is a genetic disorder which means that it is an inherited disease. The abnormal gene responsible for this disease is passed along from generation to generation by family members who carry it. Genetic disease like SCA6 occur when one of the body’s 20,000 genes does not work properly. (Gene are microscopic structures within the cells of our bodies that contain instructions for every feature a person inherits from his or her parents.)

SCA6 is an autosomal dominant disease which means that individuals of either sex are equally likely to inherit the gene and develop the disease, and the gene passes directly from one generation to the next without skipping generations. Each child of a person with SCA6 has a 50 percent chance of inheriting the gene that causes SCA6.

Gene tests can be performed for diagnostic purposes to determine what kind of Ataxia is within a person or family. Genetic testing also can be done, in some circumstances, even before there are symptoms to determine whether a person carries the abnormal gene or genes that cause Ataxia. This is called predictive or presymptomatic testing. A gene test also can be used to determine whether a fetus has an abnormal Ataxia gene. This is called prenatal testing. Anyone who is considering a predictive or prenatal test should consult with a genetic counselor to discuss the reasons for the test, the possible outcomes and how those outcomes might affect the person emotionally, medically, or socially. 

SCA6 Diagnosis

A neurologic examination can determine whether a person has symptoms typical of SCA6, and DNA-based testing can accurately detect the presence of the
abnormal gene that caused it. A neurologist is often the most helpful specialist in recognizing symptoms and diagnosing the disease that cause Ataxia.

SCA6 Research News

SCAsource provides Ataxia research news, directly from researchers to the Ataxia community. Visit SCAsource to see their full collection. Here is a collection of articles about SCA6. 

Snapshot: What is Riluzole?

Riluzole, often sold under the trade name Rilutek, is a medication used for the treatment of amyotrophic lateral sclerosis (ALS). ALS is a fatal neurodegenerative disease that mainly affects neurons Read More…

Print Friendly, PDF & Email

Spotlight: The CMRR Ataxia Imaging Team

Location: University of Minnesota, MN, USA Year Research Group Founded:  2008 What disease areas do you research? Ataxia (SCA1, SCA2, SCA3, SCA6, Friedreich Ataxia) Multiple System Atrophy – Cerebellar Ataxia Huntington’s Read More…

Print Friendly, PDF & Email

Spotlight: The Kuo Lab

Principal Investigator: Dr. Sheng-Han Kuo Location: Columbia University, New York, NY, United States Year Founded:  2012 What disease areas do you research? SCA1 SCA2 SCA3 SCA6 Tremor Essential Tremor What models and Read More…

Print Friendly, PDF & Email
Print Friendly, PDF & Email
Translate »

Join the Ataxia community today!

Become a free member for exclusive content from NAF.